Biosimilar Antibodies

Bentracimab (PB 2452) is a high-affinity neutralizing monoclonal antibody designed to specifically bind to Ticagrelor and its major active circulating metabolite. This antibody is capable of rapidly reversing the antiplatelet effects of Ticagrelor, making it an essential tool for research into the pharmacodynamics and therapeutic management of Ticagrelor-induced platelet inhibition. Bentracimab offers significant potential for studies focused on cardiovascular therapeutics and anticoagulant reversal strategies.

Afasevikumab, also known as RG 7624, RO 5553110, and NI-1401, is a fully human monoclonal IgG1κ antibody designed to neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). This antibody exhibits potent anti-inflammatory properties by targeting and inhibiting the activity of these cytokines, which are crucial mediators in the pathogenesis of various inflammatory and autoimmune disorders. Afasevikumab is primarily utilized in research focused on the therapeutic potential in treating conditions characterized by excessive or aberrant IL-17 activity.

Revdofilimab (ABBV-368) is a human IgG1 monoclonal antibody designed as an agonist targeting OX40, a constituent of the TNF receptor superfamily. OX40 is predominantly expressed on subsets of activated and memory T cells as well as T regulatory cells. This antibody facilitates the modulation of immune responses, making it a valuable tool in immunological research and therapeutic development.

Plamotamab (XmAb-13676) is a human bispecific antibody designed to target CD3 and CD20 simultaneously. This antibody facilitates the recruitment of cytotoxic T cells to CD20-expressing tumor cells, promoting targeted cell-mediated cytotoxicity. In vivo studies have demonstrated that Plamotamab effectively induces tumor regression. Additionally, it is associated with a mild hematologic reaction, highlighting its potential therapeutic benefits with manageable side effects. This product is pivotal for research focused on innovative cancer immunotherapies, particularly in the context of hematologic malignancies.

The Anti-CD32/FcγRIIA Antibody (IV.3) is a chimeric monoclonal antibody of the mouse IgG2b class, specifically designed to target human CD32/FcγRIIA. This antibody serves as a critical tool for the study of immune response modulation via Fc receptors. For accurate experimental control, it is recommended to use Mouse IgG2b kappa as the isotype control. This antibody is ideal for applications in immunology research, particularly in the investigation of Fc receptor function and its role in disease pathogenesis.

Ulenistamab (PBP1510) is a pioneering humanized IgG1 monoclonal antibody designed to specifically target the pancreatic adenocarcinoma upregulated factor (PAUF). This antibody serves as a vital tool in the investigation of pancreatic cancer (PC), offering potential insights into disease mechanisms and therapeutic avenues.

KWAR23 is a monoclonal antibody targeting human Signal Regulatory Protein Alpha (SIRPα). This antibody exhibits high affinity for SIRPα, effectively inhibiting its interaction with CD47. KWAR23 has demonstrated potential in enhancing antitumor responses, particularly when used alongside tumor-opsonizing antibodies. It is primarily utilized in the study of cancer immunotherapy, offering a promising tool for investigating checkpoint blockade strategies and tumor immune evasion mechanisms.

Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody that specifically targets complement component C2. By binding to the Sushi-2 domain of C2, Empasiprubar effectively prevents the formation of C3 convertase, thereby inhibiting the activation of both the classical and lectin complement pathways upstream of C3. This inhibition is critical in mitigating the effects of complement-mediated autoimmune disorders, such as autoimmune hemolytic anemia, and in preventing antibody-mediated rejection in organ transplantation. Additionally, Empasiprubar has demonstrated potential in preventing neuroglial and lymphoconjunctival injuries in GM1 antibody-mediated mouse models, suggesting further applications in neuroinflammatory conditions. This antibody offers a promising therapeutic approach by targeting a key point in the complement activation cascade, providing broad utility in research focused on immune regulation and complement system-mediated diseases.

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

RGX-019 is a humanized monoclonal antibody currently under investigation as a drug candidate. It specifically targets the MER proto-oncogene tyrosine kinase (MERTK), a receptor tyrosine kinase implicated in the regulation of various cellular processes including survival, migration, and differentiation. This targeted approach holds potential for therapeutic applications in oncology and diseases characterized by abnormal cell proliferation and survival.

Hersintuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting ERBB2/HER2/CD340. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. Hersintuzumab is applicable in research focused on cancer biology, particularly in studies investigating the role of the ERBB2/HER2/CD340 in tumor growth and progression.

Forimtamig (RG-6324) is a bispecific antibody designed for T-cell engagement, targeting GPRC5D and CD3. This molecule adopts a 2+1 configuration, incorporating two high-affinity binding sites for GPRC5D and a single site for CD3. It is engineered with a P329G LALA mutation in the Fc domain, which reduces binding to Fcγ receptors and C1q without affecting its interaction with the neonatal Fc receptor. The recommended isotype control for Forimtamig is Human IgG1 kappa. This antibody is pivotal in research focused on modulating immune responses, particularly in the context of cancer immunotherapy.

Sevirumab (MSL-109) is a human IgG1 monoclonal antibody designed to neutralize cytomegalovirus (CMV). This antibody specifically targets CMV glycoprotein H (gH) complexes, effectively inhibiting viral replication. It demonstrates potent antiviral activity with an EC50 value of 0.3 μg/mL, making it a valuable tool for research into CMV pathogenesis and therapeutic intervention.

The Anti-TSLP Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets thymic stromal lymphopoietin (TSLP), an important cytokine involved in the initiation of allergic inflammation and immune response. This antibody is composed of the human IgG1 heavy chain and the human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the role of TSLP in immune regulation and allergic diseases.

Pritoxaximab is a monoclonal antibody of the IgG1κ isotype designed to specifically target and neutralize Shiga toxin type 1. This antibody serves as a crucial tool in the study of bacterial pathogenesis and can be applied in research focused on the therapeutic intervention of diseases caused by Shiga toxin-producing bacteria.

Sonepcizumab (LT 1009) is a fully human monoclonal antibody targeting sphingosine-1-phosphate (S1P). This antibody is designed for investigational use in studies focusing on metastatic renal cell carcinoma (mRCC), offering a potential tool for understanding the role of S1P in tumor progression and metastasis.

Vofatamab (B-701) is a monoclonal antibody that selectively targets the fibroblast growth factor receptor 3 (FGFR3). It effectively inhibits the activation of both the wild-type and mutant forms of this receptor. This antibody is particularly useful in research focused on metastatic urothelial carcinoma (mUC), providing a critical tool for investigating the role of FGFR3 in cancer progression and potential therapeutic interventions.

Briakinumab (ABT-874) is a fully human monoclonal antibody that specifically targets and neutralizes the p40 subunit shared by the cytokines IL-12 and IL-23. This antibody's action inhibits the signaling pathways of both interleukin-12 (IL-12) and interleukin-23 (IL-23), which are crucial mediators in the inflammatory processes associated with autoimmune disorders. Briakinumab is utilized extensively in research focused on autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, providing valuable insights into the pathophysiology of these conditions and potential therapeutic approaches.

MB-311 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Lewis Y antigen. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, with an approximate molecular weight of 150 kDa. For isotype control experiments, the Human IgG1 kappa, Isotype Control is recommended. MB-311 is applicable in a range of research settings where the Lewis Y antigen is a focus of study.

VTX-1218 is a humanized IgG1 monoclonal antibody designed to specifically target VSIG4, a protein implicated in immune regulation. This antibody is engineered for high specificity and affinity, making it suitable for a variety of research applications aimed at studying immune response modulation and potential therapeutic interventions in conditions where VSIG4 is a critical factor.

Olokizumab (CDP 6038) is a humanized monoclonal antibody designed to specifically target interleukin-6 (IL-6), a cytokine implicated in the inflammatory response associated with rheumatoid arthritis (RA). This antibody is utilized primarily in the study of inflammatory mechanisms and potential therapeutic interventions for RA. Its specificity for IL-6 makes it a valuable tool in the elucidation of cytokine-driven pathways in disease pathology and in the assessment of novel anti-inflammatory strategies.

Omalizumab is a recombinant, humanized monoclonal antibody that selectively targets human immunoglobulin E (IgE), exhibiting a dissociation constant (K_D) of 0.393 nM. This antibody also interacts with human FcγRIIb receptors, with a K_D of 6.37 µM. Due to its specific mechanism of action, Omalizumab is extensively used in research focusing on persistent allergic asthma, providing a valuable tool for investigations into the pathophysiology and potential therapeutic interventions for this condition.

Turenkibart is a human monoclonal antibody of the IgG1κ subtype that specifically targets IL17A. For experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Ulviprubart (ABC-008) is a monoclonal antibody engineered to target the KLRG1 receptor, facilitating the selective depletion of highly differentiated cytotoxic T cells. This antibody is particularly useful in research focused on inclusion body myositis (IBM), providing a critical tool for investigating the pathophysiological mechanisms and potential therapeutic interventions for this condition.

The Anti-TEM7R/PLXDC2 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TEM7R/PLXDC2. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa Isotype Control is recommended.

Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody designed to specifically bind to tissue factor pathway inhibitor (TFPI). This targeted interaction makes Befovacimab an essential tool for research into hemophilia A and B, providing insights into the regulation of the coagulation cascade and potential therapeutic interventions.

Giloralimab (ABBV-927) is a potent agonistic monoclonal antibody targeting CD40. This antibody is designed to modulate immune responses, making it a valuable tool for cancer research. Its agonistic properties can potentially enhance anti-tumor immunity, providing a promising approach for investigational studies in oncology.

VGX-100 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target vascular endothelial growth factor C (VEGFC). This antibody is comprised of human immunoglobulin G1 (huIgG1) heavy chains and human lambda (huλ) light chains, exhibiting a predicted molecular weight of 143.6 kDa. For isotype control experiments, Human IgG1 kappa, Isotype Control is recommended. VGX-100 is applicable in research focusing on the modulation of angiogenesis and lymphangiogenesis, pertinent to studies in cancer and vascular biology.

Amlenetug is a human monoclonal antibody of the IgG1κ subtype that specifically targets SNCA (α-synuclein). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is ideal for research focusing on the role of SNCA in neurodegenerative disorders such as Parkinson's disease.

The Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CTLA-4 (CD152). This antibody comprises a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa. This antibody is essential for research focusing on immune checkpoint regulation and cancer immunotherapy.

Camidanlumab (HuMax-TAC) is a monoclonal antibody specifically targeting CD25, a cell-surface antigen prominently overexpressed in various hematological malignancies, while exhibiting minimal expression in normal tissues. This selective expression profile makes Camidanlumab an ideal candidate for the development of antibody-drug conjugates (ADCs) aimed at treating diseases such as lymphoma and leukemia. This antibody facilitates targeted therapeutic delivery, potentially enhancing treatment efficacy and reducing systemic toxicity.

Torvutatug is a human IgG1 κ monoclonal antibody targeting FOLR1. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Suvratoxumab (MEDI4893) is a high-affinity, long-acting human monoclonal antibody of the IgG1κ subtype, designed to target and neutralize α-toxin, a critical virulence factor of Staphylococcus aureus. This antibody has demonstrated efficacy in enhancing survival rates and reducing pulmonary damage in immunocompromised mouse models of pneumonia. Additionally, Suvratoxumab has been shown to augment the antibacterial effects of antibiotics such as Vancomycin and Linezolid, suggesting its potential utility in synergistic therapeutic strategies against S. aureus infections.

The Anti-CD71/TfR1 Antibody, also known as JR-141 antibody, is a humanized monoclonal antibody targeting the human transferrin receptor (CD71; TfR1). This antibody is the unmodified, antibody-only component of the fusion protein Pabinafusp alfa, which is utilized in therapeutic applications. For experimental controls, it is recommended to use Human IgG1 kappa as an isotype control. This product is essential for research focusing on iron metabolism, cellular iron uptake, and the pathophysiology of related disorders.

Evinacumab (REGN1500) is a human monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) and belongs to the IgG4 subclass. This antibody effectively reduces plasma lipid levels by inhibiting the activity of ANGPTL3. It has demonstrated efficacy in preclinical models, specifically in dyslipidemic mice, showcasing its potential in lipid metabolism regulation. Evinacumab is applicable for research in various lipid disorders, including homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia (both familial and non-familial), and severe hypertriglyceridemia, providing a valuable tool for studies in lipid regulation and cardiovascular disease.

Clesrovimab (MK1654) is a fully human monoclonal antibody that specifically targets the respiratory syncytial virus (RSV) fusion (F) glycoprotein. This antibody holds significant potential for use in research focused on respiratory syncytial virus infections, facilitating studies aimed at understanding viral mechanisms and developing therapeutic strategies.

Evolocumab (AMG 145) is a human monoclonal antibody specifically designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is extensively utilized in research focused on hypercholesterolemia and atherosclerotic cardiovascular disease due to its unique mechanism of action. Evolocumab effectively binds to the circulating PCSK9 protein, preventing its interaction with the low-density lipoprotein receptor (LDLR), thereby facilitating the maintenance of LDLR levels on hepatocyte surfaces and promoting LDL clearance. Additionally, Evolocumab exhibits antioxidant and cytoprotective properties, offering protection against H₂O₂-induced oxidative damage in endothelial cells. This is particularly relevant in studies exploring endothelial function under oxidative stress conditions. Furthermore, preliminary evidence suggests that Evolocumab may inhibit the activation of the TLR-4/NF-κB signaling pathway, potentially reducing inflammatory responses, which is crucial in the context of cardiovascular diseases. This multifaceted biological activity makes Evolocumab a valuable tool in cardiovascular research, particularly in the investigation of mechanisms underlying lipid metabolism and inflammation.

Tesnatilimab is a human IgG4 monoclonal antibody designed to target the immune activating receptor NKG2D. It exhibits potential immunomodulatory and anti-inflammatory properties. This antibody is particularly useful for research in inflammatory bowel disease (IBD), providing a valuable tool for understanding disease mechanisms and developing therapeutic strategies.

Naratuximab is a humanized monoclonal antibody specifically targeting CD37 (TSPAN26), a tetraspanin protein widely expressed on the surface of B cells. This antibody exhibits high specificity and affinity for CD37, making it an ideal candidate for targeted therapeutic applications, including the development of antibody-drug conjugates (ADCs). Naratuximab serves as the foundation for the ADC compound Naratuximab emtansine, which combines the targeted binding properties of naratuximab with the cytotoxic agent emtansine, offering potential applications in the treatment of B-cell malignancies.

Pamrevlumab (FG-3019) is a recombinant human monoclonal antibody specifically designed to target and bind connective tissue growth factor (CTGF). This interaction is crucial for the study of idiopathic pulmonary fibrosis (IPF), providing a valuable tool for researchers investigating the pathophysiological mechanisms and potential therapeutic interventions for this condition.

HuGAL-F2 is a monoclonal antibody derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting Fibroblast Growth Factor 2 (FGF2). This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control experiments, Human IgG2 kappa, Isotype Control is recommended. HuGAL-F2 is suitable for use in a variety of biochemical and cellular research applications to study the role and function of FGF2 in biological processes.

Telisotuzumab (ABT-700) is a human recombinant bivalent antibody designed to target the hepatocyte growth factor receptor (MET). It binds to c-Met with high affinity, effectively inhibiting c-Met signaling. This antibody demonstrates significant antitumor activity, making it a valuable tool for research in cancer therapy, particularly in studies focusing on the role of c-Met in tumor growth and metastasis.

Adezkibart is a human monoclonal antibody developed as an immunosuppressant, specifically targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Produced in the Chinese hamster ovary (CHO) cell line CHO-K1, this antibody binds selectively to FLT3LG, effectively blocking the associated signaling pathway. By inhibiting this pathway, Adezkibart reduces the immune response and demonstrates potent immunosuppressive effects. This antibody is particularly valuable for research into immune-related diseases, offering insights into immune regulation and potential therapeutic targets.

Zalutumumab is a fully human IgG1 monoclonal antibody exhibiting high affinity for the epidermal growth factor receptor (EGFR). It specifically binds to domain III of EGFR, effectively blocking the receptor's interaction with its natural ligand, EGF. This interaction inhibits the receptor's activation by steric hindrance, preventing its transition to an active conformation. Zalutumumab demonstrates binding affinities with half-maximal effective concentrations (EC50) of 7 nM for the whole IgG and 19 nM for its Fab fragment. This antibody is primarily utilized in cancer research, providing a valuable tool for investigating EGFR's role in oncogenic processes and therapeutic interventions.

Azirkitug is a humanized IgG1κ monoclonal antibody specifically targeting CCR8. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Vilamakitug (XB-2001) is a human IgG4 κ monoclonal antibody specifically targeting IL-1α. For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Veligrotug is a chimeric monoclonal antibody of the IgG1-kappa isotype, specifically targeting the insulin-like growth factor 1 receptor (IGF1R, CD221). This antibody is designed for the precise detection and inhibition of IGF1R, a receptor tyrosine kinase implicated in numerous cellular processes including cell growth, differentiation, and survival. Veligrotug is utilized in research focused on cancer biology, metabolic disorders, and developmental biology, providing valuable insights into IGF1R's role in disease pathogenesis and therapeutic interventions.